Studies of other inhibitors, such as PHA-739358, AP-24534, and DCC-2036, are expected to begin shortly. Each agent that was described in this section offers hope in cases of treatment failure with imatinib. The major challenges are to prevent the development of imatinib resistance and to find ways to eradicate all evidence of disease in all patients.
|Original language||English (US)|
|Number of pages||6|
|Journal||P and T|
|State||Published - Dec 1 2008|
ASJC Scopus subject areas
- Pharmacology (medical)